North America Testosterone Replacement Therapy Market

North America Testosterone Replacement Therapy Market Size (2024 to 2029)

The size of the testosterone replacement therapy market in North America is estimated to be worth USD 0.98 bn by 2029 from USD 0.78 bn in 2024, growing at a CAGR of 4.65% from 2024 to 2029.

The prevalence of testosterone deficiency is growing rapidly in the North American region, which is expected to accelerate the growth rate of the North American testosterone replacement therapy market. 

Governments and other international organizations, regulatory authorities, independent authorities, and non-profit organizations are launching various awareness efforts in developed and developing nations to raise knowledge about testosterone deficiency treatment. The demand for testosterone replacement therapy is predicted to rise due to increased government initiatives and awareness campaigns, which are driving the testosterone replacement therapy market.

Since the past few years, the healthcare infrastructure in emerging countries has undergone significant changes, all of which are intended to improve healthcare delivery and to include all segments of the population to stimulate market growth. Increased public spending on healthcare infrastructure and modern healthcare facilities is likely to enhance public expenditure on testosterone replacement therapy, resulting in new prospects for the market.

The key male hormone responsible for improving male sexual traits, spermatogenesis, and fertility is testosterone, another notable factor expected to support market growth. However, a lack of testosterone production causes erectile dysfunction. Conversely, a reduction in testosterone production causes erectile dysfunction. To help with the condition, testosterone replacement treatment is used.

However, during the forecast period, the North American testosterone replacement therapy market is likely to hit a patent cliff. The expiration of important medicinal patents would have an impact on large pharmaceutical firms' TRT product revenues. Furthermore, the generic versions of these pharmaceuticals would further cut market earnings because they would be far less expensive than their brand-name counterparts (branded drugs). The issue is likely to significantly impact the overall market for testosterone replacement therapy products, resulting in a substantial drop in market revenues. Furthermore, the approval of ANDAs for most of these compounds will result in fierce generic competition. As a result, patent expirations are expected to considerably impact the testosterone replacement therapy market in the near future.

This research report on the North American TRT market has been segmented & sub-segmented into the following categories.

North America Testosterone Replacement Therapy Market Analysis By Product Type

• Patches    
• Injections
• Adhesives               
• Implants  
• Oral        

North America Testosterone Replacement Therapy Market Analysis By Active Ingredient

• Testosterone Undecanoate            
• Testosterone Enanthate   
• Testosterone Cypionate   
• Methyl Testosterone        

North America Testosterone Replacement Therapy Market Analysis By Country

• The United States
• Canada
• Rest of North America

Geographically, North America had the largest market for testosterone replacement therapy globally by share in 2023. During the forecast period, the Testosterone Replacement Therapy market in North America is expected to grow at a rapid rate. This can be ascribed to an increasing target population, rising testosterone insufficiency among the elderly, and prominent manufacturers' more significant focus on developing economies like the United States and Canada.

In the North American region, the United States led the market in 2022, while Canada is expected to grow fastest during the forecast period. Factors such as the increasing geriatric population and rising hypogonadism are expected to propel the market growth in this region.

KEY MARKET PLAYERS

Companies playing a significant role in the North American testosterone replacement therapy market profiled in this report are Pfizer Inc., Allergan Plc., AbbVie Inc., Bayer AG., Eli Lilly and Company, Endo Pharmaceuticals, Kyowa Kirin International Plc., Novartis AG. and Mylan N.V. among others.